TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06395519: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Sponsor: 858 Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,159,850

Rescue Site Savings

+$1,413,720

Unlock Full NCT06395519 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06395519 Rescue Dossier →